TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Media Release
Read more
TrialNet Research Leads to FDA Approval of First Drug to Delay Type 1 Diabetes
Landmark findings from TrialNet research were instrumental in the Food and Drug Administration’s (FDA) November 17, 2022 approval of the first drug to delay type 1 diabetes (T1D) in people at risk.
TrialNet conducted the clinical study that discovered the immunotherapy drug teplizumab could delay T1D for 2+ years.
An illustration of TrialNet heroes Owen and Ella in a lab. Ella uses a tablet to plan a mission and pack supplies while Owen repairs knee armor on his red super suit.
Participant Spotlight
Read more
Meet TrialNet heroes: Owen and Ella
Meet Owen & Ella: As another modular plate locks into place Owen does a fist bump. Whenever he adds a new piece to enhance the armor on his super suit he loves making the pieces snap together, just like his favorite Legos. Always calm under pressure, Ella goes over detailed schematics for their next TrialNet T1D Heroes Academy mission.
An illustration of TrialNet heroes Citlaly & Maria practicing water bending and disc throwing at the water fountains
Participant Spotlight
Read more
Meet TrialNet heroes: Citlaly and Maria
Meet Citlaly & Maria: Super siblings united! Wind and water follow their command as Citlaly and Maria roam through downtown San Jose. Citlaly’s frisbee whistles as it whips through the air in a long arc circling the skyscrapers. In between TrialNet T1D Heroes Academy missions and studying to be a nurse, Maria tests her ability to manipulate water from the city fountains.
